Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Exclusive Forecast Study Observes Cushings Syndrome and Acromegaly Treatment Market to Incur Value Growth at 9.3% CAGR During 2018 - 2026 Persistence Market Research

Persistence Market Research
Posted on: 05 Nov 18
Exclusive Forecast Study Observes Cushings Syndrome and Acromegaly Treatment Market to Incur Value Growth at 9.3% CAGR During 2018 - 2026 Persistence Market Research

PR Newswire

NEW YORK, November 5, 2018

NEW YORK, November 5, 2018 /PRNewswire/ --

Global Cushings Syndrome And Acromegaly Treatment Market Anticipated to Grow Steadily in the Coming Years Owing to the Increasing Demand for Patient Care and Disease Management - Persistence Market Research

Persistence Market Research (PMR) delivers the key insights on the global Cushing's Syndrome and Acromegaly treatment market in its upcoming report titled "Cushing's Syndrome and Acromegaly Treatment Market: Global Industry Analysis 2013-2017 and Forecast 2018 - 2026". In terms of revenue, the global Cushing's syndrome and Acromegaly treatment market is projected to register a CAGR of 9.3% over the forecast period.

     (Logo: https://mma.prnewswire.com/media/661339/Persistence_Market_Research.jpg )

The Cushing's syndrome and Acromegaly treatment is segmented based on drug type, distribution channels and regions. Based on the drug type, the Cushing's syndrome and Acromegaly Treatment is segmented into Cushing's syndrome treatment and Acromegaly treatment. The Cushing's syndrome treatment is further sub segmented into Glucocorticoid Receptor Inhibitors, Somatostatin, Ketoconazole HRA, and other Off-label. The Acromegaly treatment is further sub segmented into Somatostatin, Glucocorticoid Receptor Inhibitors, and other Off-label. Based on the distribution channels, the global Cushing's syndrome and Acromegaly treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

Request Sample Report@ https://www.persistencemarketresearch.com/samples/24664

The Cushing's syndrome treatment segment is expected to be the leading segment in the Cushing's Syndrome and Acromegaly Treatment market over the forecast period. The Cushing's syndrome treatment segment is expected to witness a high growth at a CAGR of 9.5% over the forecast period.

The Cushing's syndrome and Acromegaly Treatment market is also segmented based on the distribution channels. The hospital pharmacies segment in the Cushing's syndrome and Acromegaly treatment market is expected to have a dominant share, while the retail pharmacies segment in the Cushing's syndrome and Acromegaly treatment is expected to grow at a CAGR of 9.7 % over the forecast period.

The growth of the global Cushing's syndrome and Acromegaly treatment market is primarily driven by its growing prevalence coupled with the growing awareness and the rate of screening. The development of healthcare infrastructure around the world coupled with the governmental support towards orphan and rare diseases is also expected to drive the growth of the Cushing's syndrome and Acromegaly treatment market. However, the high cost of drugs coupled with the lower screening rates in the developing world are factors expected to hamper the growth of the market. Government support in terms of orphan drug status and the financial and tax incentives have led to a high return on investment for the Cushing's syndrome and acromegaly treatment market.

Cushings Syndrome And Acromegaly Treatment Market Research Report Overview @ https://www.persistencemarketresearch.com/market-research/cushings-syndrome-and-acromegaly-treatment-market.asp

In the U.S., incentives include a 7-year period of market exclusivity following product launch, regardless of patent life, a waiver on Food and Drug Administration fees, and 50% tax credit on clinical studies. In the EU, Regulation offers 10-year market exclusivity, with tax credits offered by individual EU markets. In 2012, FDA Safety Innovation Act that has made rare disease drugs to progress through clinical trials activities. This has translated into driving the global sales of orphan drugs by 10% in a year between 2005-201, and a 400 orphan drugs approvals in the U.S. and EU region.

This report assesses the trends that are driving the growth of each segment of the Cushing's syndrome and Acromegaly treatment market on the global as well as regional level, and offers potential takeaways that proves substantially useful for manufacturers planning to enter the Cushing's syndrome and Acromegaly treatment market.

Download and View Report TOC, Figures and Tables @ https://www.persistencemarketresearch.com/methodology/24664

North America is expected to be the dominant regional market for Cushing's syndrome and Acromegaly treatment, accounting for a high revenue share in 2017. The U.S. Cushing's Syndrome and Acromegaly Treatment market is expected to account for a large share and to grow at a CAGR of 9.8 % over the forecast period, while Canada is expected to register a CAGR of 9.0%. Europe and Asia Pacific Cushing's Syndrome and Acromegaly treatment markets collectively are expected to grow at CAGRs of 8.9 % and 10.5%, respectively. The market is expected to shift in favour of developing regions led by Asia Pacific nation of China owing to its fast developing economy and healthcare.

Examples of key players covered in the Cushing's syndrome and Acromegaly treatment market report are Novartis AG, Corcept Therapeutics, HRA Pharma, Bristol-Myers Squibb Company, Pfizer Inc., Ipsen Biopharmaceuticals, Inc., among others. The companies are focusing on developing advanced drugs for Cushing's syndrome and Acromegaly treatment. However, the higher cost associated with Cushing's syndrome and Acromegaly treatment would hamper the growth of Cushing's syndrome and Acromegaly treatment market.

Get full Report Now @ https://www.persistencemarketresearch.com/checkout/24664

More from PMR ' s Life Sciences & Transformational HealthIntelligence:

Automatic Tube Labelling System Market : Segmented by end users - hospitals, blood banks, diagnostic laboratories, Product Type, and by Regions: https://www.persistencemarketresearch.com/market-research/automatic-tube-labelling-system-market.asp

Triple Negative Breast Cancer Treatment Market : Segmented Based on Drug Type - doxorubicin, cyclophosphamide, paclitaxel, docetaxel, carboplatin/cisplatin and others; Based on distribution channel - hospital pharmacies, specialty cancer clinics: https://www.persistencemarketresearch.com/market-research/triple-negative-breast-cancer-treatment-market.asp

High Content Screening Market : Segmentation by product types - Cell Imaging & Analysis, consumables, Software, Services ; based on Applications - Primary & Secondary Screening, Target Identification & Validation, Toxicity Studies, Compound Profiling, Others;based on industry - Pharmaceutical & Healthcare, Biotechnology, Educational Institutions, Independent CRO, Government Organizations, Others: https://www.persistencemarketresearch.com/market-research/high-content-screening-market.asp

Persistence Market Research Overview 

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact
Persistence Market Research
U.S. Sales Office:
305 Broadway, 7th Floor
New York City, NY 10007
+1-646-568-7751
United States
USA - Canada Toll-Free: 800-961-0353
Email: sales@persistencemarketresearch.com

PMR Latest News:  https://www.persistencemarketresearch.com/news

SOURCE Persistence Market Research

PR Newswire
www.prnewswire.com

Last updated on: 05/11/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.